Jaguar Health, Inc. (NASDAQ:JAGX) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET
Company Participants
Carol R. Lizak – Chief Financial Officer
Lisa A. Conte – Founder, CEO, President & Director
Operator
Good morning. Before I turn the call over to management, I’d like to remind you that management may make forward-looking statements relating to such matters as continued growth prospects for the company, uncertainties regarding market acceptance of products, the impact of competitive products and pricing, industry trends and product initiatives, including products in development stage, which may not achieve scientific objectives or meet stringent regulatory requirements.
Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. These statements are made based on current available information and management’s current assumptions, expectations and projections about future events. While management believes its assumptions, expectations and projections are reasonable in view of the currently available information, you are cautioned not to place undue reliance on forward-looking statements. The company’s actual results may differ materially from those discussed during this webcast for a variety of reasons, including those described in the forward-looking statements and Risk Factors section of the company’s Form 10-K for the year 2024, which was filed March 31, 2025, and its other filings with the SEC, which are available on the Investor Relations section of Jaguar’s website. Except as required by law, Jaguar undertakes no obligation to update or revise any forward- looking statements contained in this presentation to reflect new information, future events or otherwise.
Additionally, please note that the company supplements, its condensed consolidated financial statements presented on a GAAP basis by providing non-GAAP EBITDA and non-GAAP recurring EBITDA. Jaguar believes that the disclosure items of these non-GAAP measures provide investors with additional information that reflects
#Jaguar #Health #JAGX #Earnings #Call #Transcript